18F-PSMA-1007 is currently under investigation as a potential radiopharmaceutical targeting the prostate-specific membrane antigen (PSMA).
PSMA has considerable overexpression on most prostate cancer cells.

PSMA-PET can be used for diagnosis of prostate cancer, in particular for detection of recurrent disease with low PSA levels. 
PSMA-based imaging holds great promise to improve prostate cancer management.


Other products

18F-FDG ¹⁸F-FDOPA ¹³N-NH₃ ¹⁸F-MPPF DPA-714 ¹¹C-tracers

Interested in our products?

Contact us to discuss the possibilities.